Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), according to new analyses from the Phase 3 ASCLEPIOS trials. After two years, those on Kesimpta were nearly 20 times more likely to achieve a composite outcome characterized by an absence of […]

The post CMSC 2026: Kesimpta outperforms Aubagio in highly active relapsing MS appeared first on Multiple Sclerosis News Today.

Source: multiplesclerosisnewstoday.com